Back to top
more

Inspire Medical Systems (INSP)

(Delayed Data from NYSE)

$191.48 USD

191.48
312,318

+5.13 (2.75%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $191.38 -0.10 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Inspire (INSP) Might be Well Poised for a Surge

by Zacks Equity Research

Inspire (INSP) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Inspire Medical (INSP) Q2 Earnings Beat, Gross Margin Rises

by Zacks Equity Research

Inspire Medical (INSP) reports strong second-quarter results, reflecting a 30% revenue increase. Its new technology and expanded U.S. presence promise growth and enhanced patient care.

Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Inspire (INSP) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Inspire Medical Systems (INSP) Tops Q2 Earnings Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 328.57% and 0.01%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Inspire Medical (INSP) Gets FDA Nod for Inspire V System

by Zacks Equity Research

Inspire Medical (INSP) secures FDA approval for its advanced Inspire V therapy system, featuring an innovative neurostimulator and Bluetooth technology for enhanced patient and physician control.

Wall Street's Insights Into Key Metrics Ahead of Inspire (INSP) Q2 Earnings

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Inspire (INSP), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval

by Zacks Equity Research

Inspire Medical's (INSP) receipt of the latest CE mark certification will likely enable it to continue to deliver Inspire products globally.

Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028

by Zacks Equity Research

The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?

by Zacks Equity Research

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Three Reasons to Retain Inspire Medical (INSP) Stock for Now

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Phibro (PAHC) Q3 Earnings and Revenues Beat, Gross Margin Down

by Zacks Equity Research

Phibro's (PAHC) impressive fiscal 2024 third-quarter performance continues to be driven by the Animal Health segment.

National Vision (EYE) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

National Vision (EYE) delivers improved revenues in the first quarter of 2024 in a challenging macro environment.

Inspire (INSP) Loses -31.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Inspire (INSP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up

by Zacks Equity Research

Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.

Inspire (INSP) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Inspire (INSP) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 46.03% and 1.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Will These 5 Medical Device Stocks Beat This Earnings Season?

by Zacks Equity Research

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how INSP, MCK, FMS, NVRO and INGN are placed ahead of their earnings releases.

Gear Up for Inspire (INSP) Q1 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Inspire (INSP) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Here's Why You Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.

Haemonetics (HAE) Banks on Plasma Arm Growth Amid Rising Costs

by Zacks Equity Research

Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

Inspire Medical Systems (INSP) Stock Moves -0.8%: What You Should Know

by Zacks Equity Research

Inspire Medical Systems (INSP) closed at $241.66 in the latest trading session, marking a -0.8% move from the prior day.

Here's Why You Should Buy Bruker (BRKR) Stock Right Now

by Zacks Equity Research

Bruker's (BRKR) strong potential across the NANO and BioSpin segments bodes well for investors.